Treatment of Comorbid Depression and Substance Abuse in Young People
A cross-over study to evaluate the effects of a cognitive behavioural therapy (CBT) intervention, followed by a randomised trial of sertraline/placebo (for non-responders to CBT only) in the treatment of comorbid depression and substance misuse to improve outcome in depression and substance use levels.
Melbourne Health
50 participants
Jan 1, 2005
Interventional
Conditions
Summary
This study aims to treat a sub-sample of these young people with an adjunctive integrated CBT intervention and to examine the acceptability of this treatment approach within this population. In addition, this study seeks to explore predictors of treatment outcome so as to inform the further development of this integrated intervention. The study will also include a pilot placebo-controlled trial of sertraline for those young people who fail to or only partially respond to the CBT intervention, so as to determine whether adjunctive anti-depressant treatment improves clinical response in this population. The relationship between genetic variants of the 5-HTT and treatment response to both the CBT arm and SSRI treatment will also be explored.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This study is a naturalistic, prospective study of a targeted two-stage intervention, comprising a 10-session Cognitive Behaviour Therapy (CBT) intervention and a randomised 10-week double-blind, placebo-controlled trial of sertraline for partial and non-responders to the CBT intervention at week 6.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000675628